These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 31571403)
1. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Katoh T; Igawa Y; Yamaguchi O; Kato D; Hamada T; Kuroishi K Low Urin Tract Symptoms; 2020 Jan; 12(1):68-80. PubMed ID: 31571403 [TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650 [TBL] [Abstract][Full Text] [Related]
5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815 [TBL] [Abstract][Full Text] [Related]
7. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S; Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560 [TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Mueller ER; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Stoelzel M; Yoon SJ; Al-Shukri S; Rechberger T; Gratzke C Neurourol Urodyn; 2019 Feb; 38(2):779-792. PubMed ID: 30644570 [TBL] [Abstract][Full Text] [Related]
10. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study. Alcántara Montero A Actas Urol Esp (Engl Ed); 2019; 43(1):51-52. PubMed ID: 30025617 [No Abstract] [Full Text] [Related]
14. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972 [TBL] [Abstract][Full Text] [Related]
15. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Nitti VW; Khullar V; van Kerrebroeck P; Herschorn S; Cambronero J; Angulo JC; Blauwet MB; Dorrepaal C; Siddiqui E; Martin NE Int J Clin Pract; 2013 Jul; 67(7):619-32. PubMed ID: 23692526 [TBL] [Abstract][Full Text] [Related]
16. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714 [TBL] [Abstract][Full Text] [Related]
17. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. Khullar V; Cambronero J; Angulo JC; Wooning M; Blauwet MB; Dorrepaal C; Martin NE BMC Urol; 2013 Sep; 13():45. PubMed ID: 24047126 [TBL] [Abstract][Full Text] [Related]
19. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724 [TBL] [Abstract][Full Text] [Related]
20. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]